Private Prescription Comparison: Which Suits Your Needs?
Private Prescription Access: Wegovy Dose Compared to Mounjaro Without NHS Delays
When comparing Wegovy dose schedules to Mounjaro through private prescription in the UK, the most significant advantage is avoiding the lengthy NHS specialist weight management pathway. The NHS route typically requires a GP referral, followed by a 6+ month wait for specialist assessment, with strict BMI and comorbidity criteria that many patients struggle to meet. Private prescription services eliminate these barriers entirely, allowing direct access to both Wegovy and Mounjaro after a straightforward clinical assessment.
The private route offers identical medications to those prescribed on the NHS — genuine Novo Nordisk Wegovy and Eli Lilly Mounjaro — but with significantly faster access and more flexible ongoing support. This is particularly valuable when considering the structured dose escalation both treatments require, as private services can ensure continuity of supply without the appointment delays common in NHS specialist services. Both Wegovy and Mounjaro are available from EverydayMeds, where your prescriber can help determine which dosing schedule and mechanism might be more suitable for your individual circumstances.
Wegovy vs Mounjaro Dosing Schedule: Pricing and Value Comparison
Wegovy follows a 5-step dose escalation: 0.25mg (£79.99, weeks 1-4), 0.5mg (£94.99, weeks 5-8), 1mg (£99.99, weeks 9-12), 1.7mg (£139.99, weeks 13-16), and 2.4mg maintenance (£209.99, week 17 onwards). EverydayMeds offers structured bundles like the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99, providing the first 12 weeks of treatment in one order. New customers can apply code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices.
Mounjaro follows a different escalation pattern with 2.5mg, 5mg, 10mg, and 15mg doses, requiring dose increases every 4 weeks until reaching the effective maintenance dose. The key difference in comparing Wegovy dose schedules to Mounjaro is that Wegovy's escalation is more gradual with smaller percentage increases between doses, which may suit people who are particularly sensitive to gastrointestinal side effects. Both treatments require this careful escalation approach — skipping doses or starting at higher levels significantly increases the risk of nausea, vomiting, and treatment discontinuation.
Clinical Evidence: Wegovy Dose Compared to Mounjaro Trial Data
In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme demonstrated that the 2.4mg maintenance dose provided optimal efficacy whilst maintaining tolerability when reached through the structured escalation protocol. These trials included participants with BMI ≥30 or BMI ≥27 with weight-related comorbidities, matching the current MHRA licensing criteria.
Mounjaro's SURMOUNT trials showed similar effectiveness with its dual GIP/GLP-1 mechanism, though direct head-to-head comparisons aren't possible due to different trial designs and patient populations. Both medications have demonstrated cardiovascular benefits in dedicated outcome studies, with Wegovy's SELECT trial showing a 20% reduction in major cardiovascular events. The choice between these treatments often comes down to individual response, tolerability of the dose escalation process, and practical considerations around storage and administration.
How Wegovy Works: GLP-1 Mechanism vs Mounjaro's Dual Action
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural fullness hormone your intestines produce after eating. This mechanism works on appetite centres in the brain to reduce hunger signals whilst promoting satiety after smaller meals. The weekly injection maintains consistent blood levels, helping to reduce food cravings and the psychological drive to eat throughout the week. Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors, potentially offering broader metabolic effects. The fundamental difference when comparing Wegovy dose schedules to Mounjaro is that Wegovy focuses specifically on the proven GLP-1 pathway, whilst Mounjaro adds GIP agonism for potentially enhanced glucose and fat metabolism.
Private Prescription Ordering Process: From Assessment to Delivery
The private prescription process for both Wegovy and Mounjaro begins with a 3-minute online clinical assessment covering your weight management history, current medications, and health conditions. This assessment is reviewed by a UK-registered prescriber within 3 working days (or 24 hours with express service) who determines suitability and prescribes the appropriate starting dose. Once approved, medications are dispatched via next-day delivery using temperature-controlled cold-chain packaging to maintain the required 2-8°C storage conditions. The entire process typically takes 4-5 days from initial assessment to receiving your first prescription, compared to months through the NHS pathway. EverydayMeds operates as a GPhC-registered pharmacy (#9012878) ensuring all medications are genuine and properly stored throughout the supply chain.
Storage and Practical Considerations: Wegovy vs Mounjaro Daily Use
Both Wegovy and Mounjaro require refrigeration at 2-8°C before first use, but Wegovy offers a significant practical advantage for travel and daily life. Once removed from the fridge, Wegovy pens can be stored at room temperature below 30°C for up to 6 weeks, compared to Mounjaro's 21-day limit. This makes Wegovy more suitable for people who travel frequently or prefer not to carry medications in cool bags for extended periods. Both use pre-filled FlexTouch-style injection pens with hidden needles, making weekly administration straightforward for most people. The dose escalation process requires careful planning — many people find it helpful to set phone reminders for injection days and to track their progress through each dose level using a simple calendar or app.
Wegovy Dose Compared to Mounjaro: Which Escalation Suits Your Lifestyle?
The practical difference between Wegovy and Mounjaro dosing becomes most apparent during the initial months of treatment. Wegovy's gentler percentage increases between doses (0.25mg to 0.5mg represents a 100% increase, but from a very low starting point) may be more suitable for people with sensitive stomachs or previous experience of nausea with medications. The 4-week intervals between increases also provide adequate time for your body to adjust to each level before progressing further.
Mounjaro's escalation follows a different philosophy with potentially faster achievement of therapeutic doses, which some people prefer if they're eager to see results and confident about tolerating side effects. The choice often depends on your previous experience with appetite-affecting medications, your work and social commitments during the initial months, and whether you prefer a more gradual or assertive approach to reaching the maintenance dose. Both Wegovy and Mounjaro are available from EverydayMeds, where your prescriber can help determine which escalation schedule aligns better with your individual circumstances and treatment goals.
Private Prescription Value: Investment in Long-Term Weight Management
Understanding the total investment when comparing Wegovy dose costs to Mounjaro requires considering both the escalation period and ongoing maintenance expenses. The first 16 weeks of Wegovy (reaching 2.4mg maintenance) costs approximately £524.96 when purchasing individual pens, though bundle options like the Progress Trio provide better value and supply security. Ongoing maintenance at 2.4mg costs £209.99 monthly, making the annual cost around £2,500-3,000 including the initial escalation period.
Private prescription represents a significant investment, but many people find the immediate access, flexible ongoing support, and Reliable Supply continuity justify the cost compared to NHS uncertainty. The alternative — waiting months for NHS specialist appointments with no assurance of prescription approval — often means delayed treatment and continued health risks associated with excess weight. EverydayMeds offers discount codes (FIRST40 for new customers, DOSE25 for returning customers) and flexible ordering options to help manage these costs whilst ensuring uninterrupted access to your prescribed medication. GPhC registration (#9012878) ensures you receive genuine products with full clinical support throughout your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
